Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Trial Profile

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 01 Dec 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tivozanib (Primary) ; Sorafenib
  • Indications Renal cell carcinoma
  • Focus Registrational; Therapeutic Use
  • Acronyms TIVO-3
  • Sponsors AVEO Oncology
  • Most Recent Events

    • 17 Mar 2023 Results of subgroup analysis assessing the clinical efficacy of tivozanib in patients with advanced metastatic renal cell carcinoma previously treated with axitinib, published in the Oncologist.
    • 07 Jun 2022 Results assessing the contribution of event accumulation and data maturation on the stability of KM survival estimates, presented at the 58th Annual Meeting of the American Society of Clinical Oncology.
    • 06 Jun 2022 According to an AVEO Oncology media release, data from this trial were presented during the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting (Abstract: 4557; Poster: 48).
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top